Intensity Therapeutics Net Income

The latest net income for INTS is $-11M as of June 2026. That compares with $-13M in the prior-year period — up 11.2% year over year. That is below the sector sector average of $96M. Investors often review this figure alongside Intensity Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, INTS's net income moved from $-13M to $-11M — a 11.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Intensity Therapeutics's operating scale or balance-sheet position.

Against its sector companies, INTS currently prints $-11M for net income, while the sector average sits near $96M. That is roughly 111.6% below the sector mean. Large gaps often invite a closer look at Intensity Therapeutics's growth, margins, and balance sheet.

A net income figure of $-11M for INTS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $96M. Explore the charts below for those layers of context.

After noting INTS's net income ($-11M), review year-over-year change from $-13M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.